Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival. - Wikidata - wikimedia - TriplyDB

Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.

Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.

http://www.wikidata.org/entity/Q33756719

about

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders.Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide.The Role of Age in Neurocognitive Functioning among Adult Allogeneic Hematopoietic Cell Transplant Recipients.Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies.

P2860

Q28066710-8B1B8F93-957C-4626-96AD-D349176DCBA8 Q36928725-9CD2ACFC-3C0C-4D97-80D9-78A34C59D896 Q38381708-1798C2DA-285A-4AD5-AC58-B5DBA46FD3AD Q38629963-EEEA4622-B8BF-4A4D-A34C-9BAB8F5340C1 Q38860997-51AE0CF1-4C90-491A-A53F-A9225B99A7A8 Q40216708-42F48AE6-6364-4E58-8E8B-4A9B8BBD0376 Q41519709-ECF88B4B-2C71-4513-A797-A4CBDB256FD8

P2860

Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.

http://www.wikidata.org/entity/Q33756719

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Allotransplantation for patien ...... ing progression-free survival.

@ast

Allotransplantation for patien ...... ing progression-free survival.

@en

type

label

Allotransplantation for patien ...... ing progression-free survival.

@ast

Allotransplantation for patien ...... ing progression-free survival.

@en

prefLabel

Allotransplantation for patien ...... ing progression-free survival.

@ast

Allotransplantation for patien ...... ing progression-free survival.

@en

P1433

Q33756719-450A0867-1E81-4D2F-8763-D3D202EA5540

P1476

Q33756719-95C3A950-B4DB-45BE-ADF5-000024DDA87B

P2093

Q33756719-09DEFC29-A28B-492A-8A29-CAB725997469

Q33756719-0C523184-4830-4E8E-9AE8-7134C1630469

Q33756719-16316F2A-8663-49E6-93D6-3706143F0A32

Q33756719-17EC9E8E-2CCE-4707-A637-BAF9F09985DA

Q33756719-1D453FBC-A4F2-4F84-9416-3EE89C11D774

Q33756719-1E7F9133-F8E8-479D-BB8D-7EA35174AC1F

Q33756719-2143F466-20EC-4542-947E-E0E9EBDEF8B3

Q33756719-286510F1-473F-47B5-B907-A2D7E1F3D78E

Q33756719-2D59A701-BDD3-4D37-894D-36F75C55D79B

Q33756719-2F90594F-F188-49C3-BFE2-53A878E00F65

P2860

Q33756719-07000A6E-76F8-4194-862E-CF74D95D5927

Q33756719-0F149553-032C-4095-B3EB-9FABD392340F

Q33756719-1FE197A8-F3EA-44F1-AEA8-3AED7121EA80

Q33756719-23A459C5-132A-483A-B88B-D215E9EE803C

Q33756719-2946736A-01A9-4D9C-BFE1-7F733917B003

Q33756719-2D71A7A7-1448-46D4-A0B8-4E9D1D081FDB

Q33756719-30BC5818-CA80-448A-8C94-FA74E59FCAB2

Q33756719-3315C7D1-AB8D-4955-9E92-056700C697B2

Q33756719-3BA4CF5E-7033-434D-9483-106ED083F873

Q33756719-3D3F5867-51D6-4FC1-9E24-B3C96AAA1A46

P304

Q33756719-815802AB-BEFD-422F-B1D0-66C7D40325D7

P31

Q33756719-BD549E23-2A6D-4E1D-AD63-075DED6DCC91

P356

Q33756719-290A6775-CB5F-4AD8-9BEB-CEFF5F08F216

P433

Q33756719-B62E869F-6A99-4128-B30D-10828B7A4279

P478

Q33756719-DFAA5ECD-1355-40CB-92CC-AC6BAD0166E2

P50

Q33756719-C72EF2E5-F271-4548-A4FE-6082F877393D

Q33756719-D24367BA-C593-45AD-BDAE-5481D3D76FF5

Q33756719-EA5BA8D3-97BB-486F-B82F-9377E278FBA8

P577

Q33756719-C83829A1-2C79-4AC3-B525-38AF3A937E6F

P5875

Q33756719-1BB186E0-AE7D-4579-8B2B-7038B4D78877

P698

Q33756719-E43FED3B-6FF3-49E1-9E0C-DD5978022C37

P932

Q33756719-7095F572-7C7E-48B2-A0D9-940AA2A2D13B

P356

J.BBMT.2014.03.013

P1433

Biology of Blood and Marrow Transplantation

P1476

Allotransplantation for patien ...... ing progression-free survival.

@en

P2093

Abhinav Deol

http://www.w3.org/2001/XMLSchema#string

Alan M Miller

http://www.w3.org/2001/XMLSchema#string

Andrew S Artz

http://www.w3.org/2001/XMLSchema#string

Ann A Jakubowski

http://www.w3.org/2001/XMLSchema#string

Bipin N Savani

http://www.w3.org/2001/XMLSchema#string

Brenda W Cooper

http://www.w3.org/2001/XMLSchema#string

Brian L McClune

http://www.w3.org/2001/XMLSchema#string

César O Freytes

http://www.w3.org/2001/XMLSchema#string

Daniel J Weisdorf

http://www.w3.org/2001/XMLSchema#string

David I Marks

http://www.w3.org/2001/XMLSchema#string

P2860

Defining the intensity of conditioning regimens: working definitions

The evolving role of stem cell transplants in lymphomas

Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.

Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.

Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research

Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes.

Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.

Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies

Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure.

P304

960-968

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2014.03.013

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Hillard M Lazarus

P577

2014-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260914385

http://www.w3.org/2001/XMLSchema#string

P698

24641829

http://www.w3.org/2001/XMLSchema#string

P932

4057955

http://www.w3.org/2001/XMLSchema#string